Flagship Pioneering

‘Endless RNA’ startup Laronde raises $440m to fuel pipeline

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. Laronde is developing what it calls ‘endless’ RNA or eRNA, a circular form of the material that …

‘Endless RNA’ startup Laronde raises $440m to fuel pipeline Read More »

Pioneering a new realm of biology, startup Senda Bio expands financing to $98M

Senda Biosciences is developing drugs based on an understanding of intersystems biology—the way that humans interact with bacteria and plants. The startup, founded by Flagship Pioneering, has added $55 million to advance its three lead programs to clinical testing next year.

Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde, with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. This makes the body …

Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class Read More »